Let's Win Pancreatic Cancer 💜

Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research. bit.ly/4c1c3c7

Two recent studies highlighting the role of stroma derived plasminogen activator inhibitor proteins (PAI1 and PAI2) creating an immunosuppressive tumor microenvironment in #PancreaticCancer, via modulation of macrophage composition science.org/doi/10.1126/sc… biorxiv.org/content/10.110…

🚨New @LyssiotisLab paper led by Dr. Megan Radyk in @NatureMetabolism "NADPH-producing enzymes restrict the formation of pancreatic precancerous lesions" 🧵Follow for a tweetorial... and bonus highlight of @LabVousden co-published study and News & Views link from @WellenLab!

'X Factor' Alum, 25, Went to the ER with Acid Reflux. She was Diagnosed with Stage 4 Pancreatic Cancer (Exclusive) people.com/x-factor-alum-…

@SyedAAhmad5 Some of the team he's assembling that we have seen is smart.

That’s a great hire. And I’m a Duke fan.

#AudioVisualAbstract : Somatostatin Analogs for Preventing Postoperative @PancreaticFistula : Past Evidence Reveals New Opportunities @Kris10Goodsell @ShamSurgery rdcu.be/fbVO2 @jhatjhmi1 @SyedAAhmad5

April Issue: Waist-to-Height Ratio as a Predictor Complementary to BMI for Postoperative #PancreaticFistula After #Pancreatoduodenectomy for #PeriampullaryTumors rdcu.be/fbC58 @BotelhoDra @SyedAAhmad5 @SocSurgOnc

Georgia Hurst shares her experience navigating the intergenerational impact of Lynch syndrome and the weight of genetic inheritance in her reflection on the importance of informed reproductive choice and the reality of living with risk: hubs.li/Q049Mt_P0 #lynchsyndrome

New @MolecularCell paper from Chi Dang @Ludwig_Cancer The HIF-2 transcription factor mediates resistance to ferroptosis in #PancreaticCancer #bib30" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… Elegant mechanistic study, however Belzutifan (HIF2 inhibitor) does not work in mitigating HIF2 in this cancer.

Extrapulmonary neuroendocrine carcinoma (epNEC) is a highly lethal cancer and current therapy is very inadequate. Beyond first-line therapy with platinum/etoposide (PE), nothing reliably works well and survival is short. Even though epNEC is very different from SCLC (very different genomics), we keep treating with PE expecting good results. This retrospective study adds to the lit. FOLFIRINOX in patients with epNECs of GI origin, mostly second line, seems to have activity and is a regimen I often suggest upfront in patients with pancreatic or colorectal NECs, especially if non-small cell type. Keep also in mind that many colorectal NECs have a BRAF V600E mutation and should perhaps be treated with EC-FOLFOX/EC-FOLFIRI. onlinelibrary.wiley.com/doi/10.1111/jn…

"I believe ASCO’s principles and commitment to advancing patient care reflect my own values." Dr. Yeku highlights the power of mentorship and networking within the ASCO community. Elevate your oncology career with a global network of peers. Join us: bit.ly/4dmjeMH

Brooke Dwars learned quickly to manage her husband’s care. Nurse navigator Patricia Gambino and social worker Lauren Shaffer offer additional tips for caregivers. bit.ly/4c9PWOT

Sending love and hope to the Let's Win community this Easter. 💜

We are no longer rearranging the chairs on the deck of the Titanic. 👇🏼👇🏼 Big step forward. Everyone awaiting the completion and results of this study. Could be a major change in treatment paradigm.

Wow. 👇🏼👇🏼

Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumors ⁦@CCR_AACR⁩ aacrjournals.org/clincancerres/…

Pancreatic enzyme replacement therapy — known as PERT — may be one of the most important yet overlooked tools for #pancreaticcancer patients and survivors. In this episode of PancChat, host @AlisynCamerota sits down with Dallas Lawry, an advanced oncology certified nurse practitioner at @UCSDCancer, to break down why up to 90% of pancreatic cancer patients experience exocrine pancreatic insufficiency, how PERT works and practical tips for getting the most out of treatment — including how to time doses with meals, navigate insurance coverage and explore alternatives when costs become a barrier. Listen to the episode at 🔗 bit.ly/426sqy5. The PancChat Podcast is a collaboration between @LetsWinPC and PanCAN. 💜

April is #CancerPreventionAndEarlyDetectionMonth. There is no standard early detection test for pancreatic cancer. Awareness is one of our most powerful tools. Learn the signs and symptoms, know your family history, and don't wait to talk to your doctor💜 letswinpc.org/symptoms

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants aacrjournals.org/cancerdiscover… Phase 1 is now open & enrolling at @nyulangone @Perlmutter_CC clinicaltrials.gov/study/NCT06917… @salmanpunekar @JSabari

Very nice spatial proteomics dataset in @CR_AACR comparing primary and metastatic #PancreaticCancer from @LesinskiLab @Chrystal_Paulos @WinshipAtEmory underscoring marked differences in immune cell & stromal composition aacrjournals.org/cancerres/arti…